Showing 561-570 of 739 results for "".
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODER
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- Analysis: Vegetarian Diet during Pregnancy Lowers Risk of AD in Childrenhttps://practicaldermatology.com/news/association-between-a-maternal-vegetarian-diet-during-pregnancy-and-the-occurrence-of-atopic-dermatitis-in-children/2462188/A new study published in Pediatric Allergy and Immunology suggested that a vegetarian diet during pregnancy was associated with a reduced risk for atopic dermatitis (AD) in children. Researchers
- Can-Fite Receives Positive Response from FDA for Psoriasis Pediatric Planhttps://practicaldermatology.com/news/can-fite-receives-positive-response-from-fda-for-psoriasis-pediatric-plan/2462187/The U.S. Food and Drug Administration (FDA) gave a positive response to a study plan for piclidenoson in children suffering from psoriasis. The plan allows for children to enroll in the phase 3 pivotal clinical study aiming at registering the drug with both the FDA as well as the Europe
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.